首页|急性重症胰腺炎行双歧杆菌三联活菌胶囊联合奥曲肽的疗效分析

急性重症胰腺炎行双歧杆菌三联活菌胶囊联合奥曲肽的疗效分析

扫码查看
目的 探究在急性重症胰腺炎(SAP)治疗中行双歧杆菌三联活菌胶囊、奥曲肽联合治疗的疗效。方法 选取2021年9月—2023年8月本院收治的60例SAP患者为研究对象,并按照数字表法随机分为对照组和观察组,每组30例。其中,对照组在常规治疗基础上加行奥曲肽治疗,观察组在常规治疗基础上加行双歧杆菌三联活菌胶囊、奥曲肽联合治疗,分析对比两组临床疗效。结果 氧化应激因子指标、炎症因子指标相比,观察组治疗后水平更佳(P<0。05)。两组治疗后免疫功能指标改善明显,且观察组优于对照组(P<0。05)。观察组腹痛、呕吐、发热缓解时间与住院时间均比对照组更短(P<0。05)。结论 将双歧杆菌三联活菌胶囊、奥曲肽联合用于SAP患者临床治疗中疗效确切,有助于减轻患者炎症反应,调节患者免疫功能,加快患者病情康复速度。
Curative Effect Analysis of Bifidobacterium Triple Active Bacterial Capsules Combined with Octreotide in Treatment of Severe Acute Pancreatitis
Objective To investigate the effect of the combination therapy of bifidobacterium triple active bacterial capsules and octreotide in treatment of severe acute pancreatitis (SAP). Methods The paper treated 60 patients with SAP as subjects(from September 2021 to August 2023),and divided them into two groups with digital table method randomly. The control group (n=30) was treated with octreotide based on routine therapy,while the observation group (n=30) with bifidobacterium triple active capsules and octreotide based on routine therapy. Clinical curative effect between two groups was analyze and was compared. Results The indicators of oxidative stress factors and inflammatory factors in the observation group were better after treatment (P<0.05). After treatment,the immune function indicators improved significantly of two groups,those of the observation group were better than the control group (P<0.05). The relief time of abdominal pain,vomiting,fever and length of stay in the observation group was shorter than the control group (P<0.05). Conclusion The combination of bifidobacterium triple active bacteria capsules and octreotide can achieve definite curative effect in clinical treatment of SAP patients,can reduce inflammation,regulate immune function,and accelerate the recovery of patients.

Severe acute pancreatitisOctreotideBifidobacterium triple active bacteria capsules

吴航海、李小妹、陈燕明

展开 >

化州市人民医院,广东 化州 525100

急性重症胰腺炎 奥曲肽 双歧杆菌三联活菌胶囊

2024

智慧健康

智慧健康

ISSN:
年,卷(期):2024.10(27)